Dimerix (ASX: DXB): Nina Webster on DMX200, DMX652 & the Global Kidney Drug Opportunity
Can Dimerix build a global kidney disease business around two clinical-stage drug candidates? Dimerix (ASX: DXB) Managing Director and CEO Nina Webster joins Homodeus Research to discuss the company’s kidney disease pipeline, led by DMX200 and DMX652. DMX200 is being evaluated as a potential treatment for focal segmental glomerulosclerosis (FSGS) in the fully recruited global Phase 3 ACTION3 trial. Nina explains the trial’s clinical endpoints, the significance of its five international commercial partnerships and the milestones leading to top-line results expected in the first half of 2028…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.